Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Myrtelle Announces Positive 6-month Post-Treatment Data in Patients in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease
Myrtelle, a gene therapy company focused on developing transformative treatments for neurodegenerative diseases, has announced […]
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate
Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology […]
Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101
Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable […]
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including […]
ZAP Surgical Announces 1,000th Patient Treated with Its Groundbreaking ZAP-X Gyroscopic Radiosurgery Platform
ZAP Surgical Systems, a leading innovator in the field of surgical robotics, today announced that […]
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]
Modalis Therapeutics to Present Data for Muscular Dystrophy Treatment
Modalis Therapeutics, a pioneering company developing innovative products for the treatment of rare genetic diseases […]
Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent
Pneumagen, a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis […]
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases
Biotechnology company Maxion Therapeutics has announced it has been awarded a prestigious GBP £2 million […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more